← All Praxis Precision Medicines, INC filings

Praxis Precision Medicines, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PRAX
Praxis Precision Medicines, INC
10-K: Praxis Precision Medicines Reports Positive Phase 3 ET, DEE Data
Praxis Precision Medicines announced positive Phase 3 clinical trial results for ulixacaltamide in Essential Tremor and relutrigine in SCN2A/SCN8A DEEs, alongside significant capital raises.
NASDAQ
PRAX
Praxis Precision Medicines, INC
10-K: Praxis Precision Medicines Reports 2024 Results, Provides Clinical Program Update
Praxis Precision Medicines details its 2024 financial performance and provides updates on its clinical-stage programs, including a futility recommendation for a Phase 3 Essential Tremor study.
NASDAQ
PRAX
Praxis Precision Medicines, INC
10-K: Praxis Precision Medicines Reports Full Year 2023 Results, Outlines Pipeline Progress and Future Milestones
Praxis Precision Medicines' 2023 10-K filing details financial losses, clinical trial advancements, and strategic plans for its CNS disorder therapies.